India News | SEC Recommendations on Covaxin Emergency Use Authorisation for 2-18 Age Group Being Examined: Govt

New Delhi, Nov 30 (PTI) The Covid Subject Expert Committee's recommendations on granting emergency use authorisation to Bharat Biotech's Covaxin for the 2-18 age group are being examined and additional information has been sought, Rajya Sabha was informed Tuesday.

Responding to a question on whether the government is considering Covaxin for children under 12, Union Minister of State for Health Bharati Pravin Pawar said in a written reply the interim phase 2/3 clinical trial data on healthy volunteers aged 2 to 18 years submitted by Bharat Biotech was deliberated upon in the meeting of SEC on August 26 and October 11.

Also Read | Redmi K50 Series With MIUI 13, MediaTek Dimensity 7000 Likely To Be Launched Soon: Report.

"The committee recommended for grant of market authorization for age group of 2 to 18 years for restricted use in emergency situation subject to various conditions. This recommendation is being examined and additional information has been requested at the level of Central Drugs Standard Control Organisation (CDSCO)," Pawar said.

The CDSCO has also approved COVID-19 vaccine (ZyCoV-D) of Cadila Healthcare for restricted use in emergency situation in the age group 12 years and above, she added.

Also Read | Drinking Water Supply Schemes Worth Rs 1,816 Crore Approved for Rajasthan Under Jal Jeevan Mission.

(The above story is verified and authored by Press Trust of India (PTI) staff. PTI, India’s premier news agency, employs more than 400 journalists and 500 stringers to cover almost every district and small town in India.. The views appearing in the above post do not reflect the opinions of LatestLY)